Summary
A new penta(N-methylpyrrole carboxamide) analogue of the antibiotic distamycin has been synthesized in which the N-terminal formylamino group was replaced by a carbamoyl moiety. Itwas substantially more stable than distamycin in aqueous solution and bound to DNA with about the same affinity constant. It had an exemplary margin of selectivity against herpes simplex virus type l-infected HEp-2 cells in culture compared to uninfected control cells, and was equipotent with distamycin. For comparison, data for analogues containing fewer N-methylpyrrole carboxamide units and/or lacking the carbamoyl replacement are presented. ExtensiveDNase I footprinting experiments were conducted and revealed that all the distamycin analogues bound to AT-rich nucleotide sequences in three different restriction fragments, irrespective of how many pyrrole rings or which terminal moiety they contained. However, the relative
Introduction
Great interest is presently attached to synthetic analogues of the oligo(N-methylpyrrole carboxamide) antibiotic distamycin (1), a representative of a small group of naturally occurring compounds endowed with antiviral and antiprotozoal activity because of their ability to bind selectively to AT-rich DNA sequences. A number of synthetic compounds related to 1 have been made. Particularly interesting as regards their biological activity are the analogues 2 and 3 ( Fig. 1) possessing, respectively, four or five residues of 4-amino-1-methylpyrrole-2-carboxylic acid (Arcamone, 1989) . In the course of our investigations aimed at developing new chemotherapeutic agents endowed with high specificity of action and favourable therapeutic index, we synthesized the distamycin analogues 4 and 5 ( Fig. 1) , in which the N-terminal formylamino group is replaced with a carbamoyl moiety, and studied their binding to oligodeoxynuc1eotide duplexes by two-dimensional highresolution NMR. We found that both compounds bound strongly to the central A 3T3 sequence of the dodecamer d(CGCAAATTTGCG)2 and that compound 5 in particular gave rise to a single, stable complex with 2:1 stoichiometry (Animati et al., 1995) . The new carbamoyl derivatives were also of interest because of their expected higher stability in aqueous solution when compared to distamycin and its synthetic analogues with more than three N-methylpyrrole amino acid residues. We report here the synthesis of the new analogue 6, which has five pyrrolederived units, as well as data concerning its stability in solution, DNA affinity and antiviral and antiprotozoal Structures of the drugs used in this study: distamycin (1) and its formamido analogues 2 and 3 and the desformylamido carbamoyl analogues 4, 5 and 6. activity.We have also examined the DNA sequence specificity of all the carbamoylated analogues by means of footprinting experiments.
Materials and Experimental Procedures
General procedures and synthesis Melting points were determined by the capillary method and are uncorrected. Infra-red spectra were determined with a Perkin Elmer 881 IR spectrophotometer and 1H-NMR spectra with a Varian-Gemini 300 MHz BB. The electrospray mass spectra were recorded on a VG-Platform mass spectrometer. Silica gel 60 (230-400 mesh; Carlo Erba Reagenti) was used for flash chromatography and LiChroprep RP-18 silica (Merck) for desalting procedures. Precoated silica gel 60 F 254 sheets (Merck) were used for TLC and were developed with Ehrlich reagent or by irradiation at 254 nm. Reagent grade solvents and other chemicals were used as received.
The requisite 4-carbamoyl-1-methylpyrrole-2-carboxylic acid (7) was obtained starting from 2-(methoxycarbonyl)-1-methylpyrrole-4-carboxylic acid as already described (Animati eta!., 1995) . Aminoarnidine derivative 8 was synthesized starting from 1-methyl-4-nitropyrrole-2-carboxylic acid according to a known procedure (Arcamone et a!., 1969) .
Stability studies were performed by dissolving the compounds as the hydrochlorides in water or physiological saline or in MIlS pH 7 phosphate buffer at room temperature at a concentration of 1 mg mL-1. HPLC analysis was performed using a LiChrospher 100 RP-18, 5 mm, 250x4 mm reverse phase silica gel column and eluting with 0.1% trifluoroacetic acid in acetonitrile and water (28:72 by vol) for 15 min, followed by the same solvent mixture in the ratio 80:20 by vol. Flow rate was 1 mL min", A UV detector at 305 nm was used. -4-[1-methyl-4-[1-methyl-4-[1-methyl-4-[1-methyl-4- 
3-[1-Methyl
To a cooled (0-5°C) mixture of acid 7 (680 mg, 4 mmol) and of 3-[1-methyl-4-[1-methyl-4-[1-methyl-4-[1methyl-4-aminopyrrole-2-carboxamido]-pyrrole-2-carboxamido] -pyrrole-2-carboxamido]-pyrrole-2-carboxamido] propionamidine dihydrochloride (8) (1.9 g, 2.9 mmol) in dry DMF (150 mL) was added benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP; 2.2 g, 4 mmol) and diisopropylethylamine (1.9 mL, 10.9 mmol). The reaction mixture was stirred for 1 h at 0-5°C under nitrogen and then warmed to room temperature. After 3 h of additional stirring the resulting white precip-Antiviral Chemistry & Chemotherapy 8(3)
Corbomoyl analogues of distamycin itate was filtered off, washed with small portions ofDMF, dried and crystallized from DMF. The product was dissolved in 10 mL H 20 and charged on to a column filled with RP-18 silica gel, which was washed with H 20, eluted with CH 30H and 6, 1.1 g (50% yield), was recovered by precipitation with ethyl ether. M.p. 22TC dec; IR (KEr) mmax 3320, 1615 , 1545 , 1420 1H NMR (DMSO-d 6 ) 2.61 (t,2 H, CH 2 ) , 3.51 (q,2 H, CH 2 ) , 3.82 (s, 3 , 53.57; H, 5.25; N, 23.9. Found: C, 53.06; H, 5.77; N, 23 .04.
DNA-drug complexes
For the CD measurements, the DNA-drug complexes were formed direcdy in 1 ern optical path length quartz cuvettes by mixing appropriate volumes of the DNA and drug stock solutions in 0.05 M Tris-HCI, 0.15 M NaCI and 0.001 M EDTA buffer. The complex solutions were then titrated by adding aliquots of a drug solution at the same initial concentration in order to vary the concentration ofthe biopolymer at constant total drug concentration (C). CD spectra were recorded using a Varian Cary-219 spectrophotometer at room temperature. The qobs values were taken at the wavelength corresponding to the absorption maximum ofbound drug. Values of qlim were obtained upon extrapolation to infinite DNA concentration. The ratio between qobs and qlim is used for the determination of bound drug concentration (C B ) from the measured q values. A Scatchard plot of rlCf verses r, where r is the molar ratio of bound drug over the polymer concentration (as DNA-P) and C f is the the concentration of free drug, allowed the determination of the binding parameters K o (intrinsic binding constant) and r b (number of binding sites per nucleotide) according to the simple model of a single class of independent binding sites (Scatchard, 1949) .
Cell culture and virus
Cell line HEp-2 (an epithelial cell line derived from a human laryngeal carcinoma) was obtained from the ATCC. The cell line was tested for mycoplasma contamination with the Hoechst 33258 staining method and was found to be negative. HEp-2 cells were grown in Eagle's MEM with 10% foetal calf serum. Media were supplemented with 2 mM L-glutamine and penicillin-streptomycin (Gibco). Herpes simplex virus type 1 (HSV-1) strain HF was obtained from the ATCC. 
Cytotoxicity
Serial twofold dilutions of each test compound in 100 mL medium were prepared in quadruplicate in flat-bottomed 96-well microplates and an equal volume of cell suspension at 2xlO s cells ml,"! concentration was added. Mter 72 h of incubation at 3TC in 5% CO 2 , the plates were stained with an MIT assay (3-[4,5-dimethylthiazol-2yl]-2,5-diphenyl-tetrazolium bromide). The absorbance was measured with a Microplate Reader (Bio-Rad model 3550) at a test wavelength of 570 nm and a reference wavelength of 690 nm. Cytotoxicity was estimated in terms of cellular growth inhibition and IC so represents the concentration (u.M) required to reduce the viable cell population by half The data represent average values from two to three separate experiments.
Antiviral action
Serial twofold dilutions of test compounds in medium were prepared in flat-bottomed 96-well microplates and an equal volume of cell suspension containing 2xl0 s cells mL-l infected with virus was added. Cell cultures were previously inoculated with virus at 1000 TCID so (1 TCID so corresponds to the VirUS stock dilution that shows CPE for 50% of cells in culture after 72 h at 37"C).
After an incubation period of 72 h at 37"C under 5% CO 2 , the antiviral activity was measured based on a microscope evaluation of HSV-l-induced CPE. In all experiments each drug concentration was assayed in triplicate and averaged data were plotted in the form of a dose-effect curve from which the drug concentration (flM) required to reduce the virus-induced CPE by 50% (CPE-ID so ) was interpolated. The data (see Table 2 ) represent average values from two to three separate experiments.
Antiprotozoal activity
The antiparasitic activity of the drugs against Plasmodium falciparum (strain IT04) was measured by incubating unsynchronized cultures of P ftlciparum in erythrocytes with the compounds for 20 h. The frequency ofparasitized cells in the cultures was determined by microscopic examination of Giemsa-stained smears. The data (see Table 2 ) represent average values from three separate experiments in which 50 microscope fields were examined for each followed by treatment with Pvull. The 160 bp tyrT(A93) DNA was prepared by digestion of the plasmid pKMp27 with EcoRI and AvaI. The products were separated on a 6% polyacrylamide gel under non-denaturing conditions in TBE buffer (89 mM Tris-borate pH 8.3, 1 mM EDTA). The requisite band of DNA was excised, crushed and soaked in elution buffer (500 mM ammonium acetate, 10 mM magnesium acetate) overnight at 37°C.This suspension was filtered through a Millipore 0.45 urn filter and the DNA was precipitated with ethanol. Following washing with 70% ethanol and vacuum drying of the precipitate, the fragment was resuspended in 10 mMTris-HCI adjustedto pH 7.0 containing 10 mM NaCl. 
Preparation and labelling of DNA fragments containing modified nucleotides
The PCR protocol used to incorporate inosine and 2,6diaminopurine (DAP) residues into DNA has been recently described (Bailly & Waring, 1995a) . 275 250 
DNA purification and labelling
Plasmids pKMp27 (Drew et al., 1985) and pBS (Stratagene) were isolatedfrom Escherichia coliby a standard SDS-sodium hydroxide lysis procedure and purified by banding twice in CsCI-ethidium bromide gradients. Ethidium was removed by several isopropanol extractions followed by exhaustive dialysis againstTris-EDTA buffer.The purified plasmid was then precipitated and resuspended in appropriate buffer prior to digestion by restriction enzymes. The two pBS DNA fragments were rendered radioactive by 3Zp 3' end-labelling of the .~li1~il_~8
r 1 r 1 r l r -l r -l r l r -l r t r -l r l r l r l r --] ! ".
-. " " .......
20-'" ",-
...
• -
"i.llllĨ ĩ~:
:.
---.........
-
-'. .
--
-" , .~t,,- Numbers at the side of the gels reFer to the standard numbering scheme.
&&-

30
for 2 min and 72"C for 10 min. The reaction mixtures were then extracted with chloroform to remove the paraffin oil, and parallel reactions were pooled. The purified PCR products were 5' end-labelled with [y-32PJATP in the presence ofT4 polynucleotide kinase according to a standard procedure for labelling blunt-ended DNA fragments. After completion the labelled DNA was again purified by 6% PAGE and extracted from the gel as described above. Finally, the labelled DNA was resuspended in 10 mM Tris-HCl buffer pH 7.0 containing 10 mM NaCl.
DNase I footprinting
DNase I experiments were performed essentially according to the original protocol (Low et al., 1984) . The digestion of the samples (6 I-lL) of the labelled DNA fragment dissolved in 10 mM Tris-HCl buffer pH 7.0 containing 10 mM NaCl was initiated by the addition of 2 I-lL of a DNase I solution whose concentration was adjusted to yield a final enzyme concentration of about 0.01 units mL-1 in the reaction mixture. The extent of digestion was limited to less than 30% of the starting material so as to minimize the incidence of multiple cuts in anyone strand ('single-hit' kinetic conditions). Optimum enzyme dilutions were established in preliminary calibration experiments. After 3 min, the digestion was stopped by freezedrying, samples were lyophilized, washed once with 50 I-lL of water, lyophilized again and then resuspended in 4 I-lL of an 80% formamide solution containing tracking dyes. Samples were heated at 90°C for 4 min and chilled in ice for 4 min prior to electrophoresis.
Electrophoresis and autoradiography
DNA cleavage products were resolvedby PAGE under denaturing conditions (0.3 mm thick gels containing 8% acrylarnide and 8 M urea). Electrophoresis was continued until the bromophenol blue marker had run out of the gel (about 2.5 h at 60 W, 1600 V in TBE buffer; BRL Sequencer model 52). Gels were soaked in 10% acetic acid for 15 min, transferred to Whatman 3MM paper, dried under vacuum at 80°C,and subjected to autoradiography and/or analysed on a PhosphorImager (Molecular Dynamics 425E).
Quantification by storage phosphor imaging
The PhosphorImager was used to collect data from storage screens exposed to the dried gels overnight at room temperature. Base line-corrected scans were analysed by integrating all the densities between two selected boundaries using ImageQyant version 3.3 software. Each resolved band was assigned to a particular bond within the Carbamoyl analogues of distamycin DNA fragment by comparison of its position relative to sequencing standards generated by treatment of the DNA with formic acid followed by piperidine-induced cleavage at the purine residues (G+A track).
Results
Synthesis
The condensation of 7 and 8 (Fig. 2) to give the final product 6 was carried out either by activation of 7 as imidazolide, succinimidoyl or benzotriazole ester or by using condensing agents such as 1,3-dicyc1ohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) or PyBOP. The last method, using PyBOP in the presence of N,N-diisopropylethylamine (DIPEA), was found to give the best yield in a much shorter reaction time. Purification of the final product was performed by crystallization followed by a desalting procedure.
"Numbers in parentheses correspond to the location of each tract within the DNA fragment according to the standard numbering scheme (Bailly & Waring, 1995b) . The sequence of the 265mer is shown in Fig. 5 . HSV-l-infected cells. Also shown are results for P falciparum-parasitized erythrocytes, together with measurements of cytotoxicity towards HEp-2 cells. The antiviral potency of the new compounds was lower than that exhibited by the formylamino derivatives, but was clearly dependent on the number of N-methylpyrrole residues present in the peptide backbone. In general, antiviral potency increased with the number of Nmethylpyrrole residues in the backbone and interestingly analogue 6, which contains five pyrrole rings, had an antiherpetic activity close to that shown by 1. The antiprotozoal activity of compound 4, which contains three pyrrole rings, was similar to that of distamycin, suggesting that replacing the N-terminal formylamino group with a carbamoyl moiety does not affect the activity against P falciparum. Also in this case, the antiprotozoal activity was enhanced with increasing numbers of pyrrole units. Furthermore, compounds 4-6 were practically non-toxic to mammalian cells up to their maximum limit of solubility. As a consequence compound 6 exhibited a wide margin of selectivity in terms of the calculated indices: it was markedly superior, by somewhere between 2.5-and 50-fold (subject to the limitations of compound solubility), when compared to the derivatives having the N-terminal formylamino group as regards both its antiviral and its antiprotozoal activity. The improved therapeutic index of the new compounds is most likely related to their higher stability compared to distamycin. The degradation products of distamycin are considered to be responsible for its cytotoxicity as shown by the cytotoxic properties of a mixture of degradation products (data not shown). 
Stability in aqueous solution
A solution of 6 in distilled water showed, after 48 h, a strength corresponding to 97% of the original titre as measured by HPLC analysis. The strength of the solution was reduced to 92.5% after 96 h. By contrast, a similar solution of distamycin decayed to 85% and 46% in the same times. 
Affinity
Circular dichroism, a well-established technique for the study of distamycin-DNA complexes, allowed the comparative evaluation of DNA binding properties of the new analogues. Titration of solutions of the compounds with calf thymus DNA resulted in the appearance of a new CD band between 300 and 350 nm that directly reflects the binding of otherwise achiral distamycin molecules to DNA (Fig. 3) . The affinity of compounds 1,4, 5 and 6 for calf thymus DNA is recorded in Table 1 , where the apparent binding parameters of the complex-forming reaction, based on the admittedly over-simplified model of binding to a single class of independent sites, are compared with the values for distamycin. The new compounds 4-6 appear to have a lower affinity for calf thymus DNA than distamycin. However, within the series of the desformyl-carbamoyl analogues the affinity increased substantially as the. length of the peptide backbone increased. Table 2 shows the activity of the compounds against
Biological activity
Sequence specificity
DNase I footprinting experiments were performed using 265 bp and 117 bp restriction fragments cut from plasmid pBS. For both fragments, 3'-or 5'-labelled on one or other of the complementary strands, the products of digestion in the presence of the test drugs were resolved by PAGE. Typical autoradiograms of gels obtained with the 117mer fragment in the presence of 1,2,4 and 6 are illustrated in Fig. 4 . Similar footprinting gels resulted from exposing the DNA to 5 (data not shown). Footprints can be clearly seen around several specific sequences of the DNA. Densitometric analysis permitted us to localize and estimate the relative strength of drug binding to particular DNA sites. Fig. 5 shows differential cleavage plots obtained with the 265mer fragment. One can immediately see that all drug-protected regions are situated in AT-rich sequences of the DNA. Adjoining these protected sites are regions where the rate of nuclease cutting has been enhanced relative to the control. These regions occur mainly at GC-rich sequences. The patterns of enhancement and protection are very similar DNA and so is strictly an I+DAP track; it is characterized by much stronger bands at the DAP residues than the inosines, which helps to confirm the correctness of the sequence and the faithful incorporotion of I in place of G and DAP in place of A.
The scales on the sides of the autoradiographs correspond to the standard numbering of the fyr7(A93) sequence as represented in Fig. 7 .
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Carbamoyl analogues of distamycin for all the compounds indicating that they share comparable spectra of sequence selectivity. However, close inspection of the data reveals some differences between the compounds with a terminal formamido group (1 and 2) and those bearing an inverted retroamide group (4, 5 and 6). Drugs with a formamido group gave slightly stronger footprints than those with a retroamide bond. In particular, distamycin inhibited the cleavage of the DNA by the nuclease more efficiently than the related tris-pyrrole 4. However, the inversion of the formamido group did not greatly hinder the capacity of the drugs to recognize AT-rich sequences selectively. If one compares the differential cleavage plots for the retroamide compounds ( Fig. 5b) it appears that 4 generally gives weaker footprints than 5 and 6, whereas few significant differences between 5 and 6 can be seen. Autoradiographs obtained with the 5' and 3' end-labelled 265mer fragment confirmed that the retroamide compounds produce weaker footprints than the corresponding drugs with a formamido group, as expected from the binding constants in Table 1 . However, all compounds, including the most active derivative 6, still protect AT-rich sequences from cleavage (see the catalogue of binding sites for 6 reported in Table 3 ). It is important to note that the apparent size of the drug binding sites does not differ significantly for drugs having three or four pyrrole units. Similarly there is little difference between 5 and 6. Evidently, the size of the footprints detected with DNase I does not vary with the number ofN-methylpyrrole residues but this is probably due to the inherent inaccuracy of the enzyme in defining the exact size of drug binding sites. There exists a general consensus that DNase I detects sequence-specific interactions between drugs and DNA with high sensitivity but tends to overestimate the size of the binding sites (discussed in Bailly & Waring, 1995a) . Affinity cleaving studies using oligopyrrolecarboxamides (containing up to six N-methylpyrrolecarboxamide residues) linked to an EDTA-Fe ll group have revealed that the size of the drug binding site is directly proportional to the number of amide units in the molecule (Youngquist & Dervan, 1985) .
To investigate whether the purine 2-amino group effectively determines the preferred binding sites for distamycin and its synthetic derivatives, further footprinting experiments were carried out with homologous DNA samples substituted with inosine residues for guanosine and DAP residues for adenine. This approach has proved very successful as a means of examining the role of the guanine exocyclic 2-amino group in sequence-specific recognition of DNA by proteins and drugs including minor groove binders such as netropsin and distamycin (Bailly & Waring, 1995b) . Samples of tyrT(A93) DNA containing these modifications were prepared using PCR, and their interactions with the test drugs measured by DNase I footprinting (Fig. 6 ). DNA molecules in which all G-C and A Alfieri ef 01. The plots indicated bydashed lines reFer to the modiFied tyrT(A93) DNA Fragment containing I and DAP residues. The plots drawn as continuous lines reFer to normal tyrT(A93) DNA. Each compound was used at 0.5 mM. Other details are as in Fig. 5 .
A-T base pairs are replaced by I-C and DAP-T base pairs, respectively, still bound distamycin and its derivatives. However, the location of the footprints (presumptive drug binding sites) was completely changed. The canonical (AT-rich) and newly created (IC-rich) binding sites in the two types of DNA can be identified in Fig. 7 where the near inversion of the footprinting pattern for most ligands is clearly evident. These observations confirm our recent finding that the 2-amino group of guanine plays a decisive role in the recognition of DNA by minor groove binders (Bailly & Waring, 1995b; Waring & Bailly, 1996) . The binding of both the amide and the retroamide compounds to DNA is profoundly sensitive to whether the 2amino group of guanine is present or not.
252
Discussion
Des-formylamino-carbamoyl analogues of the pyrroleamidine oligopeptides related to distamycin represent a new class of compounds endowed with interesting biological properties and easily obtained by total synthesis. They contain, in addition to the well known 1-methyl-4aminopyrrole 2-carboxylic acid unit constituting the backbone of the biosynthetic antibiotics, a moiety of 1-methylpyrrole-2,4-dicarboxylic acid in amidated form at the N terminus. TIlls modification confers upon the compounds a distinctly higher stability in aqueous solution compared to distamycin. Their affinity for calf thymus DNA appears to be only a little lower than that of the corresponding formylamino derivatives, confirming that the formylamino group plays a small but significant role in stabilizing the DNA complex. The binding constant of 6 is of the same order of magnitude as that of distamycin. Morever, the carbamoyl derivatives retain the AT selectivity conferred by the oligopyrrole moiety. In common with distamycin and other minor groove binders, the lack of binding of the drugs to GC-containing sequences in DNA can be attributed to steric clashes with the guanine exocyclic 2amino group projecting into the minor groove of DNA. The footprinting data are fully consistent with previous studies showing that the terminal forrnamido group can be replaced with other entities such as a thioformyl group (Zimmermann et al., 1991; Singh et al., 1992) without markedly affecting the capacity of the ligand to recognize preferentially AT-rich sequences in DNA. Early studies on distamycin analogues showed that an increase in the number of N-methylpyrrolecarboxamide residues generally correlates with an increase in the affinity of the drug for DNA as well as its antiviral activity (Zimmer et al., 1972; Chandra et al, 1972; Kotler & Becker, 1972) . But the gain in activity was relatively low: for example, the selectivity index (IC so ce11lIC so virus) was found to be only three times higher with the formyl amino derivative 3, with five N-methylpyrrolecarboxamide residues, than with distamycin (Chandra et al., 1972) . Here we show that the selectivity index of 6 is 17-fold higher than that of distamycin. Thus, there is no doubt that the substitution of the terminal formamido group with a carbamoyl function greatly improves the pharmacological activity of the drugs, possibly as a result of their improved chemical stability. So far as we are aware, the carbamoyl derivative 6 is the most active compound among the many distamycin analogues with modified N-terminal groups synthesized so far. This carbamoyl penta-pyrrole derivative exhibits an interesting biological profile characterized by remarkable antiviral activity (similar to that of distamycin itself) coupled with velY low cytotoxicity. The antiherpetic properties of distamycin are well established (Verini et al., 1976; Zimmer & Wahnert, 1986 ) although its clinical development was discontinued some time ago because of toxicity problems. The antiprotozoal activity of 6 is also outstanding. In conclusion, the ample window of selectivity shown by this analogue as both an antiviral and antiparasitic agent implies a greatly improved therapeutic index of potential clinical importance, which warrants additional experiments in vivo to verify whether or not compound 6 merits specifically addressed clinical trials. \"1aring .MJ & Bailly C (1996) The influence of the exocyclic amino group characteristic of GC base pairs on molecular recognition of specific nucleotide sequences in DNA by berenil and DAPi.
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